Advanced Research & Technology Institute

Mayo Foundation for Medical Education and Research

Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Eberhard Karls Universitaet Tuebingen

Ludwig-maximilians-universitat Munchen Abeteilung Mediziniche Genetik

Bayerische Motoren Werke Aktiengesellschaft

Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh

Eberhard Karls Universitat Tubingen Medizinische F Akultat

Ludwig-maximilians-universitat Muchen

Deutsche Diabetes-forschungsgesellschaft E.v.—trager Des Deutschen Diabetes-zentrums Dusseldorf

Ludwig-maximilians-universtat Munchen

Ludwig-maximilians-universitat Munchen Abteilung Medizinische Genetik

Thomas Meitinger

Tim Matthias Strom

Michael Econs

Ken W White

Elisabeth Kremmer

Matthew J Farrer

Marius Ueffing

Ryan Uitti

Zibigniew Wszolek

Mary M Hulihan

Sara J Lincoln

Jennifer M Kachergus

Alexander Zimprich

Nadja Patenge

Friedrich Asmus

Petra Herzig

Saskia Biskup

Christian Johannes Gloeckner

Thomas Gasser

Jerzy Adamski

Timo Anderten

Martin Hrabe De Angelis

Zhongao Yu

Wolfgang Rathmann

Kenneth E White

Christian Herder

Thomas Illig

Christine Meisinger

Annette Peters

Michael Roden

Hans-Ulrich Haring

H-Erich Wichmann

Rui Wang-Sattler

Christian J Gloeckner

Petra Leitner

The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

Biomarkers for type 2 diabetes

The present invention relates to methods of diagnosing hypophosphatemic disorders.

Methods of diagnosing hypophosphatemic disorders

The present invention refers to a newly discovered gene named KASPP for Kinase Associated with Parkinsonism with Pleiomorphic Pathology or alternatively named LRRK2 for Leucine-Rich Repeat Kinase 2, its production, biochemical characterization and use for the detection and treatment of neurodegenerative disorders, such as Parkinson disease (PD) including, without limitation, sporadic PD, Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), and other synucleinopathies and/or tauopathy as well as several polymorphisms and mutations in the KASPP/LRRK2 gene segregated with PD.

KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders

The present invention relates to a kit for diagnosing a disorder comprising a reagent that detects FGF23 polypeptides and mutant FGF23 polypeptides.

Kits for diagnosing a hypophosphatemic disorder

Fibroblast growth factor (FGF23) polypeptides

A split electromechanical motor vehicle stabilizer having a locking device, and a method for roll stabilization are described. A split motor vehicle stabilizer is provided for roll stabilization, having a built-in electromechanical actuator for bracing two stabilizer parts against one another, including at least an electric motor, a gear unit, and a locking device which can lock a housing for the actuator to a rotor in the electric motor. The housing is connected to one of the stabilizer parts, and a gear unit output shaft is connected to the other stabilizer part for the purpose of transmitting torque. The housing and the rotor can be locked in only one position relative to one another after the locking device is activated, and that is the normal position for the two halves of the stabilizer in which they are not braced against one another.

Split electromechanical motor vehicle stabilizer having a locking device, and method for roll stabilization in the event of failure or shutoff of the active motor vehicle stabilizer

The present invention relates to antibodies that bind to FGF23 polypeptides and to FGF23 mutant polypeptides.

Antibodies to fibroblast growth factor (FGF23)

The invention relates to novel nucleic acids encoding a fibroblast growth factor-23(FGF23) and proteins encoded thereby, mutations in which are associated with autosomal dominant rickets (ADHR). The invention further relates to methods of diagnosing and treating hypophosphatemic and hyperphosphatemic disorders comprising inhibiting or stimulating, respectively, the biological activity of FGF23 in a patient. The invention also relates to methods of treating osteoporosis, dermatomyositis, and coronary artery disease comprising stimulating the biological activity of FGF23 in a patient.

Fibroblast growth factor (FGF23) nucleic acids

Growing community of inventors

Munich, Germany

Thomas Meitinger